1 / 33

Antithrombotic Therapy for Pediatric VAD Patients

Antithrombotic Therapy for Pediatric VAD Patients. Meloneysa Hubbard, MSN, CRNP, CCTC Director of Heart Transplant Services Children’s of Alabama. I do not have any relevant financial relationships with any commercial interests to disclose. Disclosure Statement. Objectives ?.

darrylc
Télécharger la présentation

Antithrombotic Therapy for Pediatric VAD Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antithrombotic Therapy for Pediatric VAD Patients Meloneysa Hubbard, MSN, CRNP, CCTC Director of Heart Transplant Services Children’s of Alabama

  2. I do not have any relevant financial relationships with any commercial interests to disclose. Disclosure Statement

  3. Objectives ? • Discuss the use of ventricular assist device (VAD) support in the pediatric population • Identify indications for antithrombotic therapy • Describe basic coagulation components • Discuss anticoagulation medications • Review our strategy for monitoring anticoagulation

  4. Pediatric Ventricular Assist Devices • Berlin Heart EXCOR • FDA approved pediatric VAD • Pulsatile flow device • RVAD, LVAD, BiVAD • Thoratec PVAD • HeartWare, HeartMateII • SynCardia • PumpKIN Trial

  5. Berlin Heart Implants Almond et al. Circulation 2013;127:1702-1711

  6. Morbidity and Mortality Almond et al. Circulation 2013;127:1702-1711

  7. 这是凝血过程是很容易理解是否你一定要把它理解成你的理解。这是凝血过程是很容易理解是否你一定要把它理解成你的理解。

  8. Coagulation Cascade • Feedback process of plasma protein activation • Results in converting prothrombin to thrombin • Thrombin • converts fibrinogen to fibrin • Activates platelets

  9. Balance Thrombosis Bleeding

  10. Considerations of Hemostasis • Immature coagulation • vWB factor deficiency • Heparin induced thrombocytopenia • Baseline hematology • Current hematology • Changes in patient status • Changes in nutrition

  11. Laboratory Monitoring • Anti Xa • PTT • INR • TEG • Platelet Mapping / Platelet Aggregation

  12. Thromboelastogram

  13. Thromboelastogram Maximum amplitude (MA) -body of the clot formation -represents the ultimate clot strength -indicative of platelet activity -target range 55-73

  14. Platelet Mapping • Platelet Mapping • Represents the inhibition present between clot fibrin and thrombin • Agent specific • ADP – clopidogrel, dipyridamole • AA - aspirin • Inhibition 70-95%

  15. Platelet Mapping

  16. Antithrombotic Agents • Unfractionated heparin • Antithrombin • Acetylsalicylic acid (ASA) • Dipyridamole • Clopidogrel • Low molecular weight heparin (enoxaparin) • Warfarin • Adjunctive Medications

  17. Anticoagulation Therapy • Heparin • Catalyzes the interaction between thrombin and antithrombin • Requires adequate ATIII level <70% • Initiated 24-48 hours after implant • Platelet count 50,000 • TEG MA >56 • No significant bleeding • Therapeutic monitoring with anti Xa

  18. Heparin Target Dosing

  19. Long Term Anticoagulation • Low molecular weight heparin • Catalyzes the interaction between thrombin and antithrombin • Monitor anti-Xa for target 0.6-1.0

  20. Long Term Anticoagulation • Warfarin • Vitamin K antagonist • Monitor INR for target 2.5-3.5

  21. Antiplatelet Therapy • Aspirin • Blocks arachidonic acid pathway of platelet activation • Usually started >48 hours after implant • Monitored by TEG and platelet mapping or aggregate studies • May be indicated bid

  22. Antiplatelet Therapy • Clopidogrel / Dipyridamole • Binds to adenosine di-phosphate receptors and prevents uptake • Initiated after POD 4 • Monitored by platelet mapping or aggregate studies

  23. Anticoagulation

  24. Question • A 2 month old patient supported with Berlin Heart LVAD is stable with no signs of active bleeding or pump fibrin deposits. • Anticoagulation • ASA 5mg/kg • clopidogrel 0.2mg/kg • Warfarin 0.5mg/kg • Labs • TEG/PM: MA 68; AAI 80%; ADPI 53% • INR 2.1 • What would you anticipate for this patient? • a) continue to monitor • b) increase warfarin • c) increase warfarin and clopidogrel • d) increase warfarin and decrease aspirin

  25. Anticoagulation Guidelines Berlin Heart EXCOR HeartWare HVAD Heparin Drip Inhibits coagulation pathway started 24-48 hours after implant Titrated to goal Anti Xa 0.35-0.5 U/mL Stopped once Coumadin is therapeutic Coumadin Inhibits coagulation pathway Started once bleeding resolved and tolerating PO Titrated to goal INR 2.0-3.0 Aspirin Blocks arachidonic acid pathway of platelet activation Dosed for goal AA inhibition 70-95% Clopidogrel (Plavix) Blocks adenosine di-phosphate pathway of platelet activation Dosed for goal ADP inhibition 70-90% Stopped once Coumadin is therapeutic • Heparin Drip • Inhibits coagulation pathway • started 24-48 hours after implant • Titrated to goal Anti Xa 0.35-0.5 U/mL • Stopped once Coumadin is therapeutic • Coumadin • Inhibits coagulation pathway • Started once bleeding resolved and tolerating PO • Titrated to goal INR 2.5-3.5 • Aspirin • Blocks arachidonic acid pathway of platelet activation • Dosed for goal AA inhibition 70-95 % • Clopidogrel (Plavix) • Blocks adenosine di-phosphate pathway of platelet activation • Dosed for goal ADP inhibition 70-90% • May be used as long-term therapy

  26. Patient Assessment • Pump function • Flows/Parameters • Chamber assessment • Physical assessment

  27. Patient Care Education • Medication • Indication • Administration/dosage • Side effects • Monitoring • Interactions • Physical Activity Precautions • Dietary Considerations • Illness effects • Complications of device support/anticoagulation • Home monitoring

  28. Question • Do you utilize INR Patient Home Monitoring for pediatric VAD patients? a) yes b) no

  29. Quality of Life

  30. References • Almond, C., Morales, D., Blackstone, E., Turrentine, M., Imamura, M., Massicotte, P., Jordan, L., Devaney, E., Ravishankar, C., Kanter, K., Holman, W., Kroslowitz, R., Tjossem, C., Thuita, L., Cohen, G., Buchholz, H., St. Louis, J., Nguyen, K., Neibler, R., Walters, H., Reemtsen, B., Wearden, P., Reinhartz, O., Guleserian, K., Mittchell, M., Bleiweis, M., Canter, C., Humpl, T., (2013). Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. Circulation, 127:1702-171 • Zafar, F., Chasleberry, C., Khan, M., Mehta, V., Bryant, R., Lorts, A., Wilmot,I., Jefferies, J., Chin, C., Morales, D., (2015). Pediatric heart transplant waiting list mortality in the era of ventricular assist devices. Journal of Heart and Lung Transplantation, 34:1, 82-86. • Drews, T., Kupper, F., Stiller, B., Hubler, M., Weng, Y., Berger, F., Hetzer, R., (2007). Coagulation management in pediatric mechanical circulatory support. ASAIO Journal, 53: 640-645. • Moffett, B., Gabrera, A., Teruya, J., Bomgaars, L., (2014). Anticoagulation therapy trends in children supported by ventricular assist devices: a multi-institutional study. ASAIO Journal, 60:2, 211-215 • Massicotte, M., Bauman, M., Murray, J., Almond, C., (2015). Antithrombotic therapy for ventricular assist devices in children: do we really know what to do?, (2015). 13, S343- 345.

More Related